Vitiligo - I-Vitiligo
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
I-Vitiligo yeminwe inzima kakhulu ukunyanga kunezinye iindawo. Ngaphandle nje kokungabukeki kakuhle, i-vitiligo iqhelekile kwaye ayosuleli. Kwidermatology, unyango olusebenzayo kakhulu luyi-phototherapy okanye unyango lwe-laser (excimer) ngamaxesha angama-2-3 ngeveki ubuncinane ubuncinane be-1 ngonyaka. Ukuba awukwazi ukuya esibhedlele rhoqo ngenxa yezizathu zemali okanye ngenxa yokuba uxakekile, unokuzama umatshini we-phototherapy ovunyiweyo ukuba usetyenziswe ekhaya.
Inkophe vitiligo
Vitiligo esandleni
relevance score : -100.0%
Referencesi-Vitiligo sisifo esiqhelekileyo isifo sesikhumba esibangela amabala esikhumba esimhlophe ngenxa yokulahleka kwe-melanocytes. Uphando lwakutsha nje lubonisa ukuba isifo esizilawulayo (autoimmune disease). Nangona ihlala ibonwa njengomcimbi wokuthambisa, inokuchaphazela kakhulu impilo yengqondo kunye nobomi bemihla ngemihla. Ngo-2011, iingcali zahlela uhlobo olubizwa segmental vitiligo ngokwahlukileyo kwabanye.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo ezisebenzayo zineendlela ezininzi zonyango, ezifana ne-systemic glucocorticoids, i-phototherapy, kunye ne-systemic immunosuppressants. Vitiligo ezizinzileyo zinokufumana isiqabu kwi-corticosteroids ye-topical, i-calcineurin inhibitors ye-topical, i-phototherapy, kunye neenkqubo zokutshintshwa. Inkqubela phambili yakutsha nje ekuqondeni iinkqubo ezisisiseko ze‑vitiligo ikhokelele ekuphuhlisweni konyango ekujoliswe kulo. Okwangoku, i‑JAK inhibitors zezona zithembisayo, ezibonelela ngokunyamezela okulungileyo kunye neziphumo ezisebenzayo, ngaphandle komngcipheko wokuvuselela usulelo olufihlakeleyo kunye nemiphumela ye‑systemic side effects eziqhelekileyo kunye nezinye ii‑immunosuppressive agents. Uphando oluqhubekayo lujolise ekuchongeni i‑cytokines eziphambili ezibandakanyekayo kuphuhliso lwe‑vitiligo (IFN‑γ, CXCL10, CXCR3, HSP70i, IL‑15, IL‑17/23, TNF). Ukuthintela ezi cytokines kubonise isithembiso kwiimodeli zezilwanyana kunye nezinye izigulane. Ukongeza, uphando kwi‑miRNA‑based therapeutics kunye ne‑adoptive Treg cell therapy lusaqhuba.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Alukho unyango lwaziwayo lwe-vitiligo. Kwabo banolusu olukhanyayo, i-sunscreen kunye ne-makeup zizinto zonke ezicetyiswayo. Ezinye iindlela zonyango zinokubandakanya i-steroid creams okanye i-phototherapy.
○ Unyango
#Phototherapy
#Excimer laser
#Tacrolimus ointment